Come listen to MedSIR Founders Maria Campos, Dr. Javier Cortés, and Dr. Antonio Llombart speak about the MedSIR concept and how we are currently optimizing clinical research in Oncology.

Don’t miss Dr. José Perez, Breast Cancer Specialist, speaking about the role MedSIR plays in his everyday research.

WELCOME TO MEDSIR!

Here we are dedicated to the design and management of clinical trials involving some of the most important current drugs in Oncology such as osimertinib, pembrolizumab, pertuzumab, T-DM1, olaparib, niraparib, eribulin, palbociclib, fulvestrant, radium-223 and many more and we’d be thrilled to help you transform your idea into a high-level strategic clinical trial by applying our simple method:

First off, you confidentially send us your idea… a few lines, or a short synopsis is all we need.

Then, your idea will be reviewed by our network of cancer experts while our statistician develops a realistic scenario for the study to be carried out.

Lastly, we confidentially present the proposal to a potential funder, negotiating a win-win situation that satisfies all parties.

If the project is approved, you will join our team and play a lead role in all study aspects all the way through to the publication of study results. Meanwhile, our clinical operations team professionally manages the trial, respecting ISO 9001-certified quality, while placing a major focus on accrual timelines: The faster we move, the quicker we can produce results and improve patient lives.


MedSIR INSIDE OUT – Christian Gonzalez

Today we are happy to interview our new Business Development guy, Christian Gonzalez. MedSIR Newsletter Team (MS): Thanks, Christian, for spending some time with us here today. Christian Gonzalez (CG)...
READ MORE...
The Kelly Study

This a multicenter, open-label, phase II clinical trial to assess the efficacy of pembrolizumab in combination with eribulin in female patients with hormone receptor-(HR) positive/HER2-negative metastatic breast cancer (MBC) previously treated with...
READ MORE...
The BioPER study

“A Multicentre, International, Non-controlled Phase II Trial to Identify the Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge Upon Progression to a Palbociclib Combination in ER-positive Metastatic Breast Cancer...
READ MORE...
The PHERGain Study

We are pleased to announce that PHERGain study “Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy” has achieved 40% of recruitment!!
READ MORE...
Dietary supplements and cancer: promises and realities

A dietary supplement can be defined as any vitamin, mineral, protein, enzyme, probiotic, herb, or plant substance taken to supplement dietary needs or improve body functions. Although some dietary supplements...
READ MORE...
MedSIR INSIDE OUT – Alicia Garcia

Today we are happy to spend a brief moment with Alicia Garcia, Head of Clinical Operations at MedSIR. MedSIR Newsletter Team (MS): Thanks, Alicia, for spending some time with us here today. Alicia Garcia (AG): Thank you...
READ MORE...